Sanofi Aventis unit Genzyme has unveiled a €150m expansion of its biotechnology site in Waterford, Ireland.

Around €500m has been invested in the site in past ten years. The latest upgrade has seen manufacturing capacity increased, and improvement made to laboratory facilities and administration offices.

The inauguration follows a series of high profile investments in the Irish pharmaceutical market, with both Merck and Pfizer recently unveiling new facilities in the nation.